Related Experiment Video
Updated: Oct 4, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro
L Zhao1, P Bath, S Heptinstall
1Centre for Vascular Research, University of Nottingham, Nottingham NG5 1PB.
Insights
Combining aspirin, dipyridamole, and AR-C69931 offers superior inhibition of platelet and leukocyte activation compared to individual agents. This triple therapy shows promise for better protection against vascular events.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Antiplatelet drugs are crucial in managing symptomatic vascular disease by reducing recurrent events.
- Limited experimental data exists on the combined effects of antiplatelet agents on platelet and leukocyte function.
Purpose of the Study:
- To investigate the combined effects of aspirin, dipyridamole, and AR-C69931 on platelet and leukocyte function.
- To compare the efficacy of individual agents versus combinations in inhibiting platelet and leukocyte activation.
Main Methods:
- Blood samples from healthy volunteers were used to assess platelet and leukocyte function.
- Inhibitory effects of aspirin, dipyridamole, and AR-C69931, alone and in combination, were measured.
- Platelet aggregation, P-selectin expression, platelet-leukocyte conjugate formation, and leukocyte activation were analyzed using flow cytometry.
Main Results:
- Combinations of dipyridamole, AR-C69931, and aspirin significantly inhibited platelet aggregation.
- The triple combination of all three agents was most effective in inhibiting P-selectin expression.
- Combined antiplatelet therapy, particularly the triple combination, demonstrated superior inhibition of platelet-leukocyte interactions and leukocyte activation.
Conclusions:
- Combinations of antiplatelet agents with distinct mechanisms of action can enhance inhibition of platelet and leukocyte activation.
- Triple antiplatelet therapy may offer superior protection against arterial thrombosis and atherosclerosis compared to monotherapy or dual therapy.
Abstract:
1. Antiplatelet drugs have been demonstrated to reduce the incidence of recurrent events in patients with symptomatic vascular disease. However, there is no experimental data indicating the effects of these agents when given together on platelets and leukocytes. We investigated the ability of aspirin (an inhibitor of cyclo-oxygenase), dipyridamole (an inhibitor of phospodiesterases and adenosine uptake) and AR-C69931 (a direct acting P(2T) antagonist with effects similar to those of clopidogrel which can be used in vitro) when used alone or in combination to inhibit platelet and leukocyte function. 2. Measurements of platelet and leukocyte function were performed in blood taken from normal volunteers, and the inhibitory effects of aspirin (100 micromol l(-1)), dipyridamole (10 micromol l(-1)) and AR-C66931 (100 nmol l(-1)) were determined. Platelet aggregation was induced by stirring blood with and without adenosine diphosphate (ADP) or platelet activating factor (PAF) and measured by platelet counting. Platelet P-selectin expression, platelet-leukocyte conjugate formation, and leukocyte activation were determined by flow cytometry. 3. Dipyridamole, AR-C69931, dipyridamole and AR-C69931, dipyridamole and aspirin, AR-C69931 and aspirin, and all three agents together inhibited platelet aggregation induced by stirring, ADP and PAF (P<0.01). However, it was only the combination of all three agents inhibited P-selectin expression (P<0.01). Similarly, it was the combination of all three antiplatelet agents that most consistently inhibited platelet-monocyte and platelet-neutrophil conjugate formation and monocyte and neutrophil activation. 4. Since both platelets and leukocytes are thought to contribute to arterial thrombosis and atherosclerosis, it is possible that combinations of different antiplatelet agents with different mechanisms of action may afford better protection than individual or pairs of agents used on their own.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...